VP, Nonclinical Development

Who We Are:

Osanni Bio is a development-stage therapeutics platform, headquartered in San Francisco, California. We are creative and agile innovators, relentlessly curious about finding new ways to target the biology behind diseases with the greatest unmet need and determined to do something about it.

At the center of Osanni is its innovation engine, which is optimized for discovering new scientific insights, designing novel drug concepts, and efficiently advancing programs to a meaningful proof-of-concept. Once a program is sufficiently de-risked, it graduates into its ecosystem of affiliate companies, which are equipped with the dedicated focus, specialized talent and support necessary to scale. Osanni's architecture marries the scientific depth and operational power of a centralized platform with the speed, agility and accountability of independent companies. The result: an opportunity to create and deliver more transformative medicines.

We hold patients and the physicians who care for them as our North Star. It guides our purpose, sharpens our decision-making, and defines our impact. Osanni is currently advancing programs in ophthalmology, cardiology and beyond. We are building a highly skilled team, passionate about having an impact on human health. Be part of creating an organization where people enjoy their work and their colleagues, are valued for their individuality, and can't imagine working anywhere else.

About the Role:

We are seeking an entrepreneurial, strategically minded, and scientifically rigorous VP, Nonclinical Development to support our global pharmacology and toxicology programs from lead optimization through FIH-enabling studies. Sitting on the Senior Leadership Team at a small, fast-moving biotech, this individual will provide the deep hands-on scientific judgment and organizational leadership required to advance a diverse pipeline. The ideal candidate brings a proven track record of steering multiple therapeutic modalities, including small molecules, siRNA, and antibodies, across various disease areas through successful FDA and OUS (Outside US) clinical-enabling pathways.

The right candidate thrives in a lean, fast-paced environment: self-directed, resourceful, and eager to contribute beyond the strict boundaries of their title. They build genuine loyalty and trust through authentic mentorship, operational transparency, and visible investment in their team's success, and they hold scientific rigor and operational speed in healthy tension, instinctively knowing when to push forward aggressively and when to pause for deeper data generation.

What You Will Do:

Nonclinical Strategy, Toxicology, and Pharmacology

• Program Leadership: Formulate and execute comprehensive nonclinical development strategies (pharmacology, PK/PD, and safety assessment) across multiple simultaneous programs and diverse disease areas, including readiness for transition into Osanni’s affiliate (Avian) companies once programs are sufficiently de-risked.
• Safety and Toxicology: Lead the strategic design, execution, and interpretation of non-GLP and GLP toxicology programs to support FDA IND and OUS clinical-enabling studies.
• Translational Pharmacology: Work collaboratively with Research, CMC, and Nonclinical teams to support and at times oversee in vitro and in vivo pharmacology studies to validate therapeutic hypotheses, characterize mechanisms of action, and establish PK/PD relationships that drive data-driven go/no-go decisions.
• Regulatory Authorship and Representation: Author and review high-quality nonclinical regulatory documents (including INDs, CTAs, IBs, and briefing books); serve as the primary scientific contact and subject matter expert with the FDA and OUS regulatory agencies.
• External Partnering: Select, contract, and manage CROs and external consultants, ensuring nonclinical studies are delivered on time, within budget, and to international quality and compliance standards.
• Pipeline Prioritization: As a member of the Senior Leadership Team, contribute to portfolio prioritization, capital allocation, and R&D governance decisions across the platform and future Avians.
• Scientific Advocacy: Present nonclinical data, strategy, and program milestones internally to leadership and externally to partners, investors, prospective Avian co-founders, business-development counterparties, and Key Opinion Leaders (KOLs).
• Avian Transitions: Partner with platform and Avian leadership to define nonclinical hand-off packages at program graduation, ensuring continuity of studies, data, and regulatory positioning as programs move from the innovation hub into affiliate companies.

People Leadership & Organizational Development

• Team Evolution: Manage, mentor, and scale a high-performing team, actively investing in their professional growth and career development.
• Cross-Functional Collaboration: Foster deep transparency and collaboration across the organization, partnering closely with Research, CMC, and Clinical Development teams to ensure seamless translational alignment.
• Fiscal Responsibility: Own and manage the nonclinical development budget, optimizing capital efficiency and maintaining agility across programs.
• Manage multiple priorities in a fast-paced, evolving environment, ensuring deliverables are completed accurately and on time, while performing other related duties as required.

What You Bring:

• PhD in Pharmacology, Toxicology, Molecular/Cell Biology, or a closely related scientific discipline; board certification (e.g., DABT) is a plus.
• 15+ years of progressive biopharmaceutical industry experience, with meaningful, hands-on leadership tenure within small biotech or startup environments.
• Direct, demonstrated experience successfully developing and advancing small molecules, siRNA, and antibodies.
• A proven track record of working across multiple distinct disease areas and therapeutic indications.
• Demonstrated success in authoring nonclinical regulatory sections and securing approvals for FDA INDs and OUS clinical-enabling studies.
• Expert working knowledge of GLP standards, ICH guidelines, and global regulatory expectations for nonclinical safety evaluation.
• Proven ability to manage complex CRO networks and a track record of hiring, mentoring, and developing internal scientific talent.
• Ability to travel approximately 25% of the time, dependent on program and regulatory needs.

The expected base pay range for this position is $320,000 - $360,000 plus bonus and comprehensive benefits. The base pay range reflects the target range for this position, but individual pay will be determined by additional factors such as job-related skills, experience and relevant education or training.

We are committed to creating a diverse environment and are proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

We will provide an intellectually stimulating, collegial and fast-paced environment. If you are ready to be a part of building the future of transformative medicines, then we are excited to hear from you!

#LI-hybrid